论文部分内容阅读
目的:观察补康灵联合TP方案治疗中晚期非小细胞肺癌的临床疗效和不良反应。方法:60例中晚期非小细胞肺癌患者随机分为治疗组和对照组各30例。对照组给予TP方案化疗,紫杉醇135~175 mg/m2,静脉滴注,第1天;顺铂25 mg/m2,静脉滴注,第1~3天,21 d为1个周期。治疗组在对照组治疗基础上,于化疗前1周开始口服补康灵50 mL/次,2次/d,直至化疗结束后1周。化疗2个疗程后评价2组有效率,化疗期间、化疗后不良反应及生存质量的改善情况。结果:治疗组有效率(56.67%)优于对照组(53.33%),但差异无统计学意义(P>0.05);治疗组骨髓抑制、疲劳发生率均低于对照组(P<0.05);治疗组生存质量改善,KPS评分提高,改善率达61.7%,对照组为39.2%,2组比较差异有统计学意义(P<0.05);治疗组治疗后CD3+、CD4+、CD4+/CD8+活性较治疗前增加(P<0.05),对照组较治疗前降低(P<0.05),2组治疗后比较差异有统计学意义(P<0.05)。结论:补康灵联合TP方案治疗非小细胞肺癌有较好疗效,能减轻化疗的不良反应,提高生存质量。
Objective: To observe the clinical efficacy and side effects of Bukangling combined with TP regimen in the treatment of advanced non-small cell lung cancer. Methods: Sixty patients with advanced non-small cell lung cancer were randomly divided into treatment group (n = 30) and control group (n = 30). The patients in the control group were treated with TP regimen. Paclitaxel was administered intravenously at 135-175 mg / m2 intravenously on day 1; cisplatin 25 mg / m2 was intravenously administered on days 1 to 3 and 21 days for 1 cycle. On the basis of the treatment of the control group, the treatment group began to take Buk Ling 50 mL / time, once a week before chemotherapy, twice a day until one week after chemotherapy. After two courses of chemotherapy, the effective rate of two groups was evaluated, and the improvement of adverse reactions and quality of life after chemotherapy were evaluated. Results: The effective rate (56.67%) in the treatment group was superior to that in the control group (53.33%), but the difference was not statistically significant (P> 0.05). The bone marrow suppression and the incidence of fatigue in the treatment group were lower than those in the control group (P <0.05). The treatment group improved the quality of life, KPS score improved, the improvement rate was 61.7%, the control group was 39.2%, the difference between the two groups was statistically significant (P <0.05); treatment group after treatment CD3 +, CD4 +, CD4 + / CD8 + (P <0.05), and the control group was lower than before treatment (P <0.05). The difference between the two groups after treatment was statistically significant (P <0.05). CONCLUSION: Bukangling combined with TP regimen has a good curative effect on non-small cell lung cancer, which can reduce the adverse reaction of chemotherapy and improve the quality of life.